{"entity":{"type":"insider","cik":"0001294596","url":"/insider/0001294596","json_url":"/insider/0001294596.json","name":"Wysenski Nancy","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":15,"n_filings":9,"first":"2011-11-16","last":"2023-05-10","span_basis":"filed_date"},"name_variants":[{"name":"Wysenski Nancy","source":"filing","n_filings":9,"first_seen":"2011-11-16","last_seen":"2023-05-10"}],"transactions":[{"id":8205261,"accession":"0001127602-23-015117","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001127602-23-015117","line_url":"/filing/0001127602-23-015117#line-3","is_derivative":false,"issuer_cik":"0001294596","issuer_name":"Alkermes plc.","issuer_ticker":"ALKS","issuer_name_source":null,"issuer_url":"/issuer/0001294596","owner_cik":"0001294596","owner_name":"Wysenski Nancy","owner_display_name":"Wysenski Nancy","owner_url":"/insider/0001294596","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":41250.0,"shares_display":"41,250","price_per_share":31.2433,"price_display":"31.24","price_state":"stated","total_value":1288786.125,"total_display":"1,288,786.12","total_whole":"1,288,786","shares_owned_after":15829.0,"shares_owned_after_display":"15,829","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-09","filed_date":"2023-05-10","scope":"insider"},{"id":2745436,"accession":"0001127602-20-007701","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-20-007701","line_url":"/filing/0001127602-20-007701#line-1","is_derivative":false,"issuer_cik":"0001294596","issuer_name":"Alkermes plc.","issuer_ticker":"ALKS","issuer_name_source":null,"issuer_url":"/issuer/0001294596","owner_cik":"0001294596","owner_name":"Wysenski Nancy","owner_display_name":"Wysenski Nancy","owner_url":"/insider/0001294596","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6940.0,"shares_display":"6,940","price_per_share":19.65,"price_display":"19.65","price_state":"stated","total_value":136371.0,"total_display":"136,371.00","total_whole":"136,371","shares_owned_after":11242.0,"shares_owned_after_display":"11,242","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-24","filed_date":"2020-02-25","scope":"insider"},{"id":7914659,"accession":"0001127602-19-011890","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-19-011890","line_url":"/filing/0001127602-19-011890#line-2","is_derivative":false,"issuer_cik":"0001294596","issuer_name":"Alkermes plc.","issuer_ticker":"ALKS","issuer_name_source":null,"issuer_url":"/issuer/0001294596","owner_cik":"0001294596","owner_name":"Wysenski Nancy","owner_display_name":"Wysenski Nancy","owner_url":"/insider/0001294596","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":445.0,"shares_display":"445","price_per_share":33.06,"price_display":"33.06","price_state":"stated","total_value":14711.7,"total_display":"14,711.70","total_whole":"14,712","shares_owned_after":4302.0,"shares_owned_after_display":"4,302","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-03-14","filed_date":"2019-03-18","scope":"insider"},{"id":7914656,"accession":"0001127602-19-011890","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-19-011890","line_url":"/filing/0001127602-19-011890#line-1","is_derivative":false,"issuer_cik":"0001294596","issuer_name":"Alkermes plc.","issuer_ticker":"ALKS","issuer_name_source":null,"issuer_url":"/issuer/0001294596","owner_cik":"0001294596","owner_name":"Wysenski Nancy","owner_display_name":"Wysenski Nancy","owner_url":"/insider/0001294596","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3857.0,"shares_display":"3,857","price_per_share":33.09,"price_display":"33.09","price_state":"stated","total_value":127628.13,"total_display":"127,628.13","total_whole":"127,628","shares_owned_after":3857.0,"shares_owned_after_display":"3,857","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-21","filed_date":"2019-03-18","scope":"insider"},{"id":9268240,"accession":"0001209191-12-031713","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-12-031713","line_url":"/filing/0001209191-12-031713","is_derivative":false,"issuer_cik":"0000875320","issuer_name":"VERTEX PHARMACEUTICALS INC / MA","issuer_ticker":"VRTX","issuer_name_source":null,"issuer_url":"/issuer/0000875320","owner_cik":"0001294596","owner_name":"Wysenski Nancy","owner_display_name":"Wysenski Nancy","owner_url":"/insider/0001294596","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":180000.0,"shares_display":"180,000","price_per_share":64.27150866666666,"price_display":"64.27","price_state":"stated","total_value":11568871.56,"total_display":"11,568,871.56","total_whole":"11,568,872","shares_owned_after":32232.0,"shares_owned_after_display":"32,232","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-05-14","filed_date":"2012-06-01","scope":"insider","n_lines":2},{"id":2274384,"accession":"0001209191-12-028591","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-12-028591","line_url":"/filing/0001209191-12-028591","is_derivative":false,"issuer_cik":"0000875320","issuer_name":"VERTEX PHARMACEUTICALS INC / MA","issuer_ticker":"VRTX","issuer_name_source":null,"issuer_url":"/issuer/0000875320","owner_cik":"0001294596","owner_name":"Wysenski Nancy","owner_display_name":"Wysenski Nancy","owner_url":"/insider/0001294596","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":180000.0,"shares_display":"180,000","price_per_share":64.27150866666666,"price_display":"64.27","price_state":"stated","total_value":11568871.56,"total_display":"11,568,871.56","total_whole":"11,568,872","shares_owned_after":32604.0,"shares_owned_after_display":"32,604","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-05-14","filed_date":"2012-05-16","scope":"insider","n_lines":2},{"id":2368691,"accession":"0001209191-12-027021","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001209191-12-027021","line_url":"/filing/0001209191-12-027021","is_derivative":false,"issuer_cik":"0000875320","issuer_name":"VERTEX PHARMACEUTICALS INC / MA","issuer_ticker":"VRTX","issuer_name_source":null,"issuer_url":"/issuer/0000875320","owner_cik":"0001294596","owner_name":"Wysenski Nancy","owner_display_name":"Wysenski Nancy","owner_url":"/insider/0001294596","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":38009.0,"shares_display":"38,009","price_per_share":62.10125628140703,"price_display":"62.10","price_state":"stated","total_value":2360406.65,"total_display":"2,360,406.65","total_whole":"2,360,407","shares_owned_after":31394.0,"shares_owned_after_display":"31,394","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-05-08","filed_date":"2012-05-09","scope":"insider","n_lines":3},{"id":2368667,"accession":"0001209191-12-027021","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-12-027021","line_url":"/filing/0001209191-12-027021#line-5","is_derivative":false,"issuer_cik":"0000875320","issuer_name":"VERTEX PHARMACEUTICALS INC / MA","issuer_ticker":"VRTX","issuer_name_source":null,"issuer_url":"/issuer/0000875320","owner_cik":"0001294596","owner_name":"Wysenski Nancy","owner_display_name":"Wysenski Nancy","owner_url":"/insider/0001294596","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":147695.0,"shares_display":"147,695","price_per_share":54.5,"price_display":"54.50","price_state":"stated","total_value":8049377.5,"total_display":"8,049,377.50","total_whole":"8,049,378","shares_owned_after":31394.0,"shares_owned_after_display":"31,394","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-05-07","filed_date":"2012-05-09","scope":"insider"},{"id":2208612,"accession":"0001209191-12-004858","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-12-004858","line_url":"/filing/0001209191-12-004858#line-1","is_derivative":false,"issuer_cik":"0000875320","issuer_name":"VERTEX PHARMACEUTICALS INC / MA","issuer_ticker":"VRTX","issuer_name_source":null,"issuer_url":"/issuer/0000875320","owner_cik":"0001294596","owner_name":"Wysenski Nancy","owner_display_name":"Wysenski Nancy","owner_url":"/insider/0001294596","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6042.0,"shares_display":"6,042","price_per_share":37.0,"price_display":"37.00","price_state":"stated","total_value":223554.0,"total_display":"223,554.00","total_whole":"223,554","shares_owned_after":21893.0,"shares_owned_after_display":"21,893","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-01-19","filed_date":"2012-01-23","scope":"insider"},{"id":9122529,"accession":"0001209191-11-061087","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-11-061087","line_url":"/filing/0001209191-11-061087#line-1","is_derivative":false,"issuer_cik":"0000875320","issuer_name":"VERTEX PHARMACEUTICALS INC / MA","issuer_ticker":"VRTX","issuer_name_source":null,"issuer_url":"/issuer/0000875320","owner_cik":"0001294596","owner_name":"Wysenski Nancy","owner_display_name":"Wysenski Nancy","owner_url":"/insider/0001294596","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":28.9,"price_display":"28.90","price_state":"stated","total_value":144500.0,"total_display":"144,500.00","total_whole":"144,500","shares_owned_after":27935.0,"shares_owned_after_display":"27,935","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-12-12","filed_date":"2011-12-13","scope":"insider"},{"id":9075420,"accession":"0001209191-11-056355","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-11-056355","line_url":"/filing/0001209191-11-056355#line-1","is_derivative":false,"issuer_cik":"0000875320","issuer_name":"VERTEX PHARMACEUTICALS INC / MA","issuer_ticker":"VRTX","issuer_name_source":null,"issuer_url":"/issuer/0000875320","owner_cik":"0001294596","owner_name":"Wysenski Nancy","owner_display_name":"Wysenski Nancy","owner_url":"/insider/0001294596","role":"Officer (EVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":606.0,"shares_display":"606","price_per_share":29.77,"price_display":"29.77","price_state":"stated","total_value":18040.62,"total_display":"18,040.62","total_whole":"18,041","shares_owned_after":32935.0,"shares_owned_after_display":"32,935","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-11-15","filed_date":"2011-11-16","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":15,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":3,"open_market":true},{"code":"S","label":"Open-market sale","n":12,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":15},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001520262","name":"Alkermes plc.","url":"/issuer/0001520262","role":"Director","n_filings":3,"first_seen":"2019-03-18","last_seen":"2023-05-10"},{"type":"issuer","type_label":"ISSUER","cik":"0000875320","name":"VERTEX PHARMACEUTICALS INC / MA","url":"/issuer/0000875320","role":"Officer (EVP, Chief Commercial Officer)","n_filings":6,"first_seen":"2011-11-16","last_seen":"2012-06-01"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001294596","retrieved_at":"2026-08-26T10:40:01+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}